When Water Tablets Stop Being Enough
A person living with heart failure may notice that shoes no longer fit, weight is climbing and walking across a room takes more effort. These can be signs of fluid building up faster than ordinary treatment can remove it. Doctors often increase water tablets first, but swollen tissues around the gut can make oral furosemide harder to absorb reliably. The next step has commonly meant an intravenous (IV) dose at a clinic or hospital.
Furoscix ReadyFlow offers another way to deliver an established medicine. Approved by the US Food and Drug Administration in July 2026 through a supplemental drug application, the prefilled autoinjector delivers 80 mg of furosemide under the skin in about 10 seconds. It is intended for selected adults with fluid buildup related to chronic heart failure or chronic kidney disease. The novelty is the delivery system, not the drug itself.
Why an Injection Can Work When Tablets Struggle
Furosemide helps the kidneys remove excess salt and water through urine. Tablets are inexpensive and familiar, but their effect can be unpredictable during worsening congestion. IV treatment gets the drug directly into the bloodstream, although it generally requires a staffed setting. ReadyFlow instead deposits a concentrated dose beneath the skin, from which it is absorbed.
The FDA prescribing information describes a comparison in 19 healthy adults. After the 80 mg ReadyFlow injection, the total amount of drug reaching the bloodstream was close to that from two 40 mg IV doses given two hours apart. The researchers also recorded similar urine output and salt removal at specified times. In straightforward terms, the injection delivered the medicine effectively and produced a strong water-removing response. Those results come from a controlled study, not a trial showing that the autoinjector prevents hospital admissions in people with worsening heart failure.
Ten Seconds Instead of Wearing a Pump for Five Hours
Furoscix was already available as an on-body infusor before ReadyFlow. The earlier system delivers 80 mg over five hours: 30 mg in the first hour and the remainder over the following four. ReadyFlow administers the same total amount in seconds, without a device attached to the body for the rest of the morning or afternoon.
The injection is brief; the increased urination is not. In studies cited by the FDA, its effect lasted up to about six hours. The instructions say users should expect more urine within roughly an hour and have bathroom access for up to six hours. For someone with limited mobility, planning that part of the day—and arranging help if needed—may be more consequential than the injection itself.
What Clinical Research Actually Shows
ReadyFlow’s approval relied partly on how much drug entered the bloodstream and how effectively it increased urine production. Those measurements help establish that an injected dose acts as intended. They are separate from evidence about emergency visits, symptom relief or overall costs of care.
An earlier randomized pilot study, AT HOME-HF, offers some clinical context. Published in JACC: Heart Failure in 2024, it enrolled 51 people with worsening heart failure. Those assigned to subcutaneous furosemide lost about 2 kg more weight by day three than those receiving usual care, and some symptom measures improved. The trial did not show a statistically significant benefit on its main combined outcome. Crucially, it tested the five-hour on-body infusor, not the 2026 ReadyFlow autoinjector.
In an accompanying independent editorial, cardiologists Jeroen Dauw and Wilfried Mullens pointed to practical barriers, including fixed dosing and the difficulty of checking blood salts and kidney function when patients are treated away from hospital. They also noted low potassium in roughly one-fifth of participants receiving subcutaneous furosemide in the small pilot study. Their assessment supports further study of outpatient treatment, but cannot be treated as a clinical endorsement of ReadyFlow specifically.
Promising Results in the Thigh and Arm—But an Abdomen-Only Label
In October 2026, MannKind reported results of a separate crossover study in which its autoinjector was tested in the thigh and upper arm. Compared with IV dosing, the reported relative drug exposure was 91.3% for the thigh and 92.7% for the arm. Urine volume and the amount of sodium passed in urine were also similar across the studied approaches. That suggests the drug can be absorbed effectively from more than one part of the body.
The current FDA instructions still permit ReadyFlow injections only into the abdomen. The study announcement did not change the approved directions. Patients must use an abdominal site at least two inches from the navel, avoiding irritated or damaged skin, and keep the injector firmly in place until the yellow plunger fills its window. If a dose appears incomplete, the instructions say to contact the healthcare provider rather than automatically inject again. MannKind also reported a comparison with the older five-hour infusor, but acknowledged that the underlying studies involved different groups of people.
Who Can Use It and What Home Treatment Requires
ReadyFlow is labeled for adults with edema associated with chronic heart failure or chronic kidney disease, including nephrotic syndrome. Although another Furoscix presentation can be used in certain children weighing at least 43 kg, ReadyFlow itself is for adults. Its fixed 80 mg dose may not suit a patient who needs a different amount. It is prescribed for a treatment episode, with a return to oral diuretics as soon as practical, rather than for indefinite daily injections.
Before prescribing it, clinicians need to assess symptoms, blood pressure, kidney function and the ability to manage treatment at home. Furosemide can cause dehydration, low potassium or sodium, low blood pressure and worsening kidney function; injection-site redness, pain and bruising can also occur. Patients need instructions on when to use the dose, what to monitor afterward and when blood tests or a follow-up call are due. Severe breathlessness at rest, chest pain, fainting or confusion still call for urgent assessment, not a home injection in place of emergency care.
The single-use injector is stored at room temperature in its carton, away from light, and discarded in an appropriate sharps container. It should not be refrigerated or frozen. These details matter to anyone receiving a supply in advance of a possible episode of fluid overload.
Getting a Prescription and Understanding the Cost
ReadyFlow has launched in the United States, but it is not an over-the-counter product to collect from a neighborhood pharmacy. According to the manufacturer’s patient instructions, a clinician generally sends the prescription to FUROSCIX Direct. That service checks insurance coverage, contacts the patient to confirm details and arranges delivery through a partner pharmacy to the patient’s home. It also offers access to an on-call pharmacist for questions about using the product. Patients should expect a call or text to verify insurance and shipping details before the order is completed, so delivery is not necessarily immediate.
What a patient pays depends on insurance and eligibility for assistance, not on the low cost of generic furosemide tablets. FUROSCIX Direct advertises commercial copay support and a patient-assistance program. People with Medicare Part D may be eligible for a payment plan that spreads prescription expenses across the year; spreading payments does not reduce the underlying cost. No single patient price can be stated responsibly without knowing the plan and coverage decision.
For a stable patient whose swelling is getting worse, the practical gain is a prescribed injectable dose that can be administered without a five-hour wearable infusion or a visit solely for IV access. The next questions for care teams are concrete: who qualifies, how quickly the prescription arrives, when blood tests are checked and whether an outpatient treatment episode actually reduces the need for hospital care.
References
- U.S. Food and Drug Administration. (2026). FUROSCIX (furosemide injection): Prescribing information and ReadyFlow instructions for use, NDA 209988, supplement 007. FDA prescribing information.
- MannKind Corporation. (2026, July 24). MannKind announces FDA approval of Furoscix ReadyFlow. Company announcement.
- MannKind Corporation. (2026, October 9). MannKind data at HFSA 2026 highlights new evidence supporting Furoscix ReadyFlow. GlobeNewswire.
- Konstam, M. A., et al. (2024). Avoiding Treatment in Hospital With Subcutaneous Furosemide for Worsening Heart Failure: A Pilot Study (AT HOME-HF). JACC: Heart Failure, 12(11), 1830–1841. https://doi.org/10.1016/j.jchf.2024.07.015.
- Dauw, J., & Mullens, W. (2024). Redefining Boundaries in Heart Failure Care: The Potential and Pitfalls of Subcutaneous Furosemide. JACC: Heart Failure, 12(11), 1842–1844. https://doi.org/10.1016/j.jchf.2024.08.014.
- FUROSCIX. (2026). How to get FUROSCIX: Prescriptions and home delivery. Patient instructions.
- FUROSCIX. (2026). Access and support: FUROSCIX Direct. Prescriber and patient support.
- FUROSCIX. (2026). Support and out-of-pocket cost assistance. Patient support options.